Join our daily newsletter At The Bell to receive exclusive market insights
Compumedics Ltd (ASX:CMP) has posted its highest-ever sales figure, netting $33 million in the first half of FY26, also seeing shipped revenues climb over +30% versus 1H FY25, with that figure reflecting a readout of $31 million.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with Compumedics Ltd and is intended for informational purposes only.
Shares saw a modest jump out the gate, up around +5% to just shy of 35cps on Thursday. Sales at $32.8M were +6% higher than those in 1H FY25, with the company pointing to stronger demand across its core sleep and neuro product portfolio on the back of a deliberate run at the U.S. market.
(Context: The Aussie company’s SomfitD sleep testing device was recently approved for use in the U.S. by the FDA, only back in September 2025.)
As for its market-disrupting Magnetoencephalography (MEG) tech, the company reported one order in the first half of FY26 with more expected to follow into July and beyond. Revenue strength was attributed to improved sales conversion with MEG system installation pricing expected to continue improving.
On the back of all of this, Compumedics is flagging guidance of an expected $70M revenue for FY26, including earnings before tax of up to $9M. And, the company anticipates 2H FY26 to be stronger still, with bank funding to be tapped.
At the same time, the Australian health company is launching a $2M cost-out program designed to cut costs, where possible, in a way that maintains smart investment into the cash-generative parts of the biz.
“With Somfit D planned for launch in the second half and a $20M pipeline already identified, alongside MEG opportunities advancing and additional bank funding capacity being progressed, we believe the company is well positioned to deliver on FY26 guidance and continue building a higher quality earnings profile with increasing recurring and connected platform contribution,” CMP chief Dr David Burton said.
CMP last traded at 34.5cps.
Join the discussion: See what HotCopper users are saying about Compumedics Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
